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Abstract
Objectives. The aims of this study were to establish whether, in patients with gout, MPO is released from
neutrophils and urate is oxidized to allantoin and if these effects are attenuated by allopurinol.
Methods. MPO, urate, allantoin and oxypurinol were measured in plasma from 54 patients with gout and
27 healthy controls. Twenty-three patients had acute gout, 13 of whom were receiving allopurinol, and 31
had intercritical gout, 20 of whom were receiving allopurinol. Ten additional gout patients had samples
collected before and after 4 weeks of allopurinol.
Results. Plasma MPO and its specific activity were higher (P< 0.05) in patients with acute gout not
receiving allopurinol compared with controls. MPO protein in patients’ plasma was related to urate con-
centration (r= 0.5, P<0.001). Plasma allantoin was higher (P<0.001) in all patient groups compared with
controls. In controls and patients not receiving allopurinol, allantoin was associated with plasma urate
(r= 0.62, P< 0.001) and MPO activity (r= 0.45, P<0.002). When 10 patients were treated with allopurinol,
it lowered their plasma urate and allantoin (P= 0.002). In all patients receiving allopurinol, plasma allantoin
was related to oxypurinol (r= 0.65, P<0.0001). Oxypurinol was a substrate for purified MPO that
enhanced the oxidation of urate.
Conclusion. Increased concentrations of urate in gout lead to the release of MPO from neutrophils and
the oxidation of urate. Products of MPO and reactive metabolites of urate may contribute to the pathology
of gout and hyperuricaemia. At low concentrations, oxypurinol should reduce inflammation, but high
concentrations may contribute to oxidative stress.
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Introduction
Hyperuricaemia is critical for the development of gout and is
also linked to numerous pathologies [1, 2]. Painful attacks of
gout occur when crystals of monosodium urate precipitate
within joints and promote an acute inflammatory response.
Other inflammatory diseases associated with hyperuricae-
mia include diabetes, hypertension, pre-eclampsia,
metabolic syndrome, renal failure and cardiovascular dis-
ease (CVD) [3, 4]. Whether urate is a causative factor in
these diseases is controversial, but evidence linking hyper-
uricaemia to their pathology continues to mount.
The pernicious effects of urate are often attributed to its
ability to activate the inflammasome [5]. It is also pro-
posed to act as a pro-oxidant when oxidized to its radical
[6]. Recently urate was demonstrated to be a physio-
logical substrate for the neutrophil enzyme MPO [7]. This
haem enzyme uses hydrogen peroxide (H2O2) to oxidize
chloride to hypochlorous acid (HOCl) [8], but under
physiological conditions will also convert urate to the
urate radical. The urate radical is readily reduced by as-
corbate [9], but it also gives rise to several electrophiles
including dehydrourate, 5-hydroxyisourate and urate
hydroperoxide [7]. These species will react with
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endogenous nucleophiles or break down to the stable bio-
marker allantoin.
In gout, MPO is likely to be discharged from neutrophils
when they are recruited to affected joints and attempt to
phagocytose urate crystals. Urate should compete with
chloride and be oxidized by MPO. Whether MPO is pre-
sent in the circulation of patients with gout and oxidizes
urate to allantoin is unknown. This is clinically relevant
because MPO contributes to cardiovascular risk [10] and
both hyperuricaemia and gout are associated with an
increased risk of CVD and death [1114].
Successful long-term management of gout requires
sustained reduction of plasma urate to <360mM [15].
Allopurinol, which inhibits xanthine oxidoreductase, thereby
preventing the production of urate [16], is the most com-
monly used urate-lowering therapy. Allopurinol is rapidly
metabolized by aldehyde oxidase to oxypurinol and H2O2
[17]. By virtue of its longer half-life, oxypurinol exerts most
of the inhibitory effects on xanthine oxidoreductase.
We hypothesize that during acute inflammation in gout,
MPO will be released from neutrophils and oxidize urate to
reactive intermediates that will contribute to the adverse
effects of hyperuricaemia. The aims of this study were to
determine in patients with gout whether MPO is released
from neutrophils and oxidizes urate and if these effects
are attenuated by allopurinol.
Patients and methods
Subjects
Patients with gout as defined by ARA preliminary classifi-
cation criteria were recruited [18]. Acute gout was defined
as the presence of a red, hot, swollen joint typical for gout
and intercritical gout was defined as a patient with a con-
firmed diagnosis of gout with no current inflammatory joint
symptoms. Healthy controls were randomly selected from
the Christchurch electoral role. Patient demographic and
clinical details were collected. Laboratory assessment
included plasma urate and oxypurinol concentrations.
Peripheral blood for MPO and allantoin was collected
and processed as previously described [19]. Ethical
approval was obtained from the Upper South A and B
Regional Ethics Committees, New Zealand. Written in-
formed consent was obtained from each patient.
Laboratory assays
Urate concentrations in plasma were measured by the
Trinder reaction and using HPLC with ultraviolet (UV)
light detection [20]. These methods gave comparable re-
sults. Plasma oxypurinol concentrations were measured
as previously described [21]. There is currently no vali-
dated therapeutic range for plasma oxypurinol. In healthy
volunteers, xanthine oxidase is maximally inhibited
(90% inhibition) at a plasma oxypurinol concentration of
34 mM [22].
Plasma MPO was determined by ELISA as described
previously [23]. In this assay, MPO is initially captured with
a monoclonal MPO antibody and its activity is determined
using H2O2 and Amplex Red. Then the amount of MPO
that was bound to the plate is determined using a poly-
clonal MPO antibody. Plasma allantoin was measured by
stable isotope dilution mass spectrometry as described
elsewhere [24].
The production of HOCl by purified MPO in an in vitro
assay was determined by measuring the accumulation of
taurine chloramine [10]. Reactions were started by adding
50 mM H2O2 to 20 nM MPO in 10 mM phosphate buffer
(pH 7.4) containing 140 mM sodium chloride and 5 mM
taurine. The reactions were stopped after 4 min by
adding 20mg/ml of catalase and accumulated taurine
chloramine was determined. Tyrosine (10mM), which is a
good substrate for compound II of MPO [8], was included
with the purines to determine whether they acted by pro-
moting formation of this redox intermediate, which is
unable to oxidize chloride. None of the purines reacted
directly with taurine chloramine. MPO was obtained from
Planta (Vienna, Austria) and had a purity index of 0.82.
Oxidation of urate (300 mM) by purified MPO (25 nM) with
various concentrations of oxypurinol in 50 mM phosphate
buffer (pH 7.4) was started by adding H2O2 (50 mM) and
stopped after 30 min by adding catalase (10 mg/ml).
Production of allantoin from urate oxidation was mea-
sured using stable isotope dilution mass spectrometry
as described elsewhere [24]. Xanthine, urate, allopurinol
and oxypurinol were obtained from Sigma (St Louis, MO,
USA). All other reagents were of the highest analytical
grade available.
Statistical analysis
Data are expressed as the median and interquartile range
(IQR). The statistical analysis of differences between
group medians was carried out using either the
MannWhitey rank sum test, analysis of variance
(ANOVA) on ranks or the Wilcoxon signed rank test.
Correlations were tested using Spearman’s rank order
correlation. In all cases significance was accepted as
P< 0.05. Insufficient sample was available to analyse
MPO in one patient with acute gout receiving allopurinol.
Results
Patient demographics
Fifty-four patients with gout and 27 healthy controls of a
similar age range and gender mix were recruited. They
had peripheral blood samples obtained on a single occa-
sion. The patients were allocated into four groups: acute
gout not receiving allopurinol (n= 10), acute gout receiving
allopurinol (n= 13), intercritical gout not receiving allopur-
inol (n= 11) and intercritical gout receiving allopurinol
(n= 20). An additional 10 patients with gout had peripheral
blood samples taken prior to commencing treatment with
allopurinol and again after 4 weeks of therapy. No patients
were receiving other urate-lowering therapies such as
probenecid or febuxostat. Demographic and clinical
details are shown in Table 1.
The plasma urate concentrations of patients not on allo-
purinol with either acute gout [median 552 mM (IQR
496586), n= 10] or intercritical gout [median 530 mM
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(IQR 460570), n= 11] were significantly elevated
(P< 0.05) compared with controls [median 359 mM (IQR
302427), n= 27]. Plasma urate concentrations of patients
receiving allopurinol were not significantly different from
controls (data not shown).
Plasma MPO is increased in patients with acute gout
MPO protein and MPO enzyme activity were measured in
the plasma of controls and the four patient groups, who
were sampled on one occasion, to determine whether
gout is associated with systemic increases in this neutro-
phil-derived protein. Both the activity and concentration of
the enzyme were measured because MPO is susceptible
to inactivation and is inhibited in plasma by ceruloplasmin
[23]. Plasma MPO protein was significantly higher
(P< 0.05) in patients with acute gout not receiving allopur-
inol [median 41.9 ng/ml (IQR 19.689.8), n= 10] compared
with healthy controls [median 18.4 ng/ml (IQR 14.521.5),
n= 27] (Fig. 1A), but not in patients with intercritical gout
not receiving allopurinol [median 31.2 ng/ml (IQR
13.959.7), n= 11]. The enzyme activity of MPO in
plasma was significantly higher (P< 0.05) in patients
with acute gout not receiving allopurinol [median
37.0 ng/ml (IQR 11.877.8), n= 10] compared with healthy
controls [median 6.3 ng/ml (IQR 4.39.5), n= 27] (Fig. 1B).
MPO activity was not significantly elevated in patients
with intercritical gout not receiving allopurinol [median
11.6 ng/ml (IQR 5.717.4), n= 11]. The specific activity of
MPO (MPO activity/MPO protein) was significantly higher
in patients with acute gout not on allopurinol compared
with controls (Fig. 1C), but not for patients with intercritical
gout not on allopurinol. Allopurinol had no significant
effects on the levels of MPO protein, MPO activity or the
enzyme’s specific activity (Fig. 1AC).
To determine whether plasma urate affects the release
of MPO from neutrophils, we assessed its relationship
with plasma MPO protein and activity in all acute and in-
tercritical gout patients irrespective of whether they were
receiving allopurinol (Fig. 1D). In these patients, plasma
urate concentration was significantly associated with
MPO protein (r= 0.50, P= 0.0002, n= 53) and MPO activity
(r= 0.29, P= 0.04, n= 53). The effect of urate on MPO ac-
tivity was more significant (P= 0.005) when patients were
split into normouricaemic [median 8.1 ng/ml (IQR
6.611.0), n= 23] and hyperuricaemic individuals [median
12.9 ng/ml (IQR 7.933.6), n= 30]. Collectively these data
suggest that acute gout leads to an increase in plasma
MPO that is associated with the concentration of urate.
Allopurinol did not appear to affect the concentrations
of MPO.
Plasma allantoin is increased in patients with gout
To assess whether urate is oxidized in patients with gout,
we measured allantoin in plasma. The concentration of
allantoin in plasma of both patients with acute gout not
on allopurinol [median 6.4 mM (IQR 4.27.98), n= 10] and
intercritical gout not on allopurinol [median 4.9 mM (IQR
4.25.4), n= 11] was significantly higher (P< 0.05) than
that in healthy controls [median 2.6 mM (IQR 1.53.8),T
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n= 27] (Fig. 2A). The concentration of allantoin was similar
in acute patients irrespective of whether they were receiv-
ing allopurinol, but in intercritical patients allantoin was
significantly higher (P< 0.001) in those treated with allo-
purinol [median 10.6mM (IQR 7.812.7), n= 20] compared
with those not receiving allopurinol (Fig. 2A).
There was a significant correlation between the concen-
trations of allantoin and urate in the plasma of controls
and gout patients not treated with allopurinol (r= 0.62,
P< 0.0001, n= 48) (Fig. 2B). In this group there was also
a significant correlation between the concentrations of al-
lantoin and MPO activity in plasma (r= 0.45, P< 0.002,
n= 48) (Fig. 2C). There was a weaker correlation of MPO
protein with allantoin (r= 0.31, P< 0.035, n= 48). Patients
treated with allopurinol were excluded from these ana-
lyses because of its positive effect on allantoin in the in-
tercritical group. These data indicate that urate is oxidized
in patients with gout and that oxidation is associated with
higher concentrations of urate and MPO.
Effects of allopurinol on the oxidation of urate
A notable feature of the data on plasma allantoin was that
even though allopurinol lowered urate concentrations in
patients with gout, it did not lower the concentration of
allantoin. In fact, the plasma concentration of allantoin
was highest in patients with intercritical gout treated
with allopurinol (Fig. 2A). To directly assess the effect of
allopurinol on allantoin and MPO levels, we selected 10
additional patients with gout who were commenced on
allopurinol and looked for changes in urate, allantoin and
MPO after 4 weeks of therapy. In a paired analysis, allo-
purinol was found to lower circulating urate (P= 0.002)
(Fig. 3A) as well as the plasma concentration of allantoin
(P= 0.002) (Fig. 3B). It had no significant effect on concen-
trations of MPO protein or MPO activity (data not shown).
These data were in conflict with those in Fig. 2A for the
effect of allopurinol in patients with intercritical gout.
Therefore we assessed how the concentration of oxypur-
inol affected the plasma concentration of allantoin in all
patients receiving allopurinol. As shown in Fig. 3C, there
was a strong association between plasma oxypurinol con-
centrations and allantoin (r= 0.65, P< 0.0001, n= 42).
Allopurinol and oxypurinol are analogues of hypoxan-
thine and xanthine and are potential targets for oxidation
by reactive oxygen species and peroxidases. Therefore,
to understand how oxypurinol might affect the oxidation of
FIG. 1 MPO in plasma of patients with gout
(A) MPO protein was measured in plasma from healthy
controls (Cont), patients with acute gout off (AG) or on
allopurinol (AG + AP) and patients with intercritical gout off
(ICG) and on allopurinol (ICG + AP). (B) MPO activity was
also measured in these groups and (C) the specific MPO
activity was calculated from the ratio of MPO activity to
MPO protein. Box plots show medians with 25th and 75th
percentiles as boundaries. Whiskers are for the 10th and
90th percentiles. Symbols: closed circle indicates an
outlier. Groups were compared using analysis of variance
on ranks or the MannWhitney rank sum test. Asterisk
indicates P< 0.05 compared with the control. NS: not
significant. (D) The relationship between plasma urate and
plasma MPO protein in all patients with gout. The asso-
ciation was determined using Spearman’s rank order
correlation.
FIG. 2 Allantoin in plasma of patients with gout
(A) Allantoin was measured in plasma from controls and
patients with gout and analysed as described in Fig. 1.
Closed circle indicates an outlier. Allantoin was compared
with (B) plasma urate or (C) plasma MPO activity. Filled
and empty dots are for controls and patients, respectively.
Correlations were determined using Spearman’s rank
order correlation. NS: not significant.
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urate, we determined the effects of these purines on the
in vitro activity of purified MPO by assessing whether they
interfere with its production of HOCl (Fig. 4A). Oxypurinol
inhibited MPO by 50% (IC50) at 6.8 mM (Fig. 4A), while
xanthine had an IC50 of 2.8 mM (not shown). Allopurinol
and hypoxanthine had no effect (data not shown).
Inhibition by oxypurinol reached a maximum of only
75% and was less effective in the presence of tyrosine
(Fig. 4A), which prevents accumulation of an inactive
form of MPO [8]. These results suggest that oxypurinol
is a substrate for the redox intermediates of MPO. To
test this possibility we determined how oxypurinol af-
fected the oxidation of urate by MPO. Adding oxypurinol
to a system containing MPO, urate and H2O2 enhanced
the production of allantoin (Fig. 4B). Importantly, allantoin
was not formed in the absence of urate. Oxypurinol also
enhanced the conversion of urate to allantoin by MPO in a
dose-dependent manner (Fig. 4C). These results indicate
that oxypurinol is a substrate for MPO that can promote
the oxidation of urate.
Discussion
Neutrophils swarm into the joints of patients with gout to
phagocytose MSU crystals [2] and in the process they
generate numerous cytokines and release enzymes into
the extracellular milieu [26]. MPO is the most abundant
enzyme discharged by neutrophils [8]. Therefore it is sur-
prising that until now there have been no reports on how
MPO contributes to the pathology of gout. Our identifica-
tion of elevated MPO in the circulation of patients with
acute gout and its association with increased oxidation
of urate strongly suggest that it will participate in the
sequelae of gout, including the predisposition to CVD.
Our results indicate that during an attack of gout neu-
trophils are stimulated and release MPO. The significant
correlation between the concentrations of urate and MPO
in plasma is in accord with the established findings that
MSU crystals activate the NACHT, LRR and PYD do-
mains-containing protein 3 (NALP3) inflammasome,
which promotes an influx of neutrophils to the site of
FIG. 4 Oxypurinol as an inhibitor and substrate of MPO
(A) The effect of oxypurinol on the production of hypo-
chlorous acid (HOCl) by purified MPO. Reactions were
started by adding 50 mM hydrogen peroxide (H2O2) to
20 nM MPO in 10 mM phosphate buffer (pH 7.4) contain-
ing 140 mM chloride and 5 mM taurine with (open circle) or
without (closed circle) 10mM tyrosine. Reactions were
stopped after 5 min by adding 20 mg/ml of catalase and
the accumulated taurine chloramine was measured.
(B) Oxidation of urate to allantoin by MPO in the absence
and presence of 200mM oxypurinol and (C) with increas-
ing concentrations of oxypurinol. Reactions were started
by adding 50 mM H2O2 to 50 mM phosphate buffer (pH 7.4)
containing 25 nM MPO, 300 mM urate and varying con-
centrations of oxypurinol. After 30 min of production,
allantoin was measured using mass spectrometry. Data
are means and ranges of duplicates and are representa-
tive of at least three separate experiments. IC50: half
maximal inhibitory concentration.
FIG. 3 The effects of allopurinol and oxypurinol on plasma
concentrations of urate and allantoin
Plasma samples were collected from 10 patients pre-
senting with gout and again 4 weeks after treatment with
allopurinol. (A) Urate and (B) allantoin were measured
before and after treatment. Statistically significant differ-
ences (P< 0.05) were determined using the Wilcoxon
signed rank test; closed circle indicates an outlier.
(C) Plasma oxypurinol was measured in all patients
receiving allopurinol and compared with the concentration
of allantoin. The correlation was determined using
Spearman’s rank order correlation.
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crystal deposition [27]. These crystals also stimulate neu-
trophils to produce superoxide and release proteins from
their granules, including MPO [26, 28]. The higher specific
activity of MPO in patients with acute gout suggests that
neutrophils release fully active MPO during an attack of
gout but over time it becomes inactivated either by its
substrate H2O2 [29] or its product HOCl [30].
We found that allantoin, the oxidative metabolite of
urate, is elevated in patients with gout not receiving allo-
purinol. This result is important because it demonstrates
that urate is oxidized during episodes of gout so that oxi-
dative stress is a feature of this inflammatory pathology.
The strong association of allantoin with urate suggests
that the inflammation induced by urate promotes oxidative
stress. The correlation between allantoin and the activity
of MPO also suggests that MPO actively produces oxi-
dants during episodes of gout. Although significant, this
correlation was not strong, which suggests that other oxi-
dants also contribute to the oxidation of urate, and it may
also reflect the fact that MPO sticks avidly to the endo-
thelium so that only a minor fraction is detected in plasma
[31]. During inflammation in gout, MPO would be ex-
pected to produce mainly HOCl, as occurs in numerous
other inflammatory diseases [19, 3234]. As illustrated in
Fig. 5, our data suggest that MPO will also produce urate
radicals during inflammation. Some of these radicals will
break down to allantoin, which should be considered a
stable biomarker of urate oxidation. However, urate rad-
icals can also scavenge nitric oxide, combine with super-
oxide to form a reactive hydroperoxide or give rise to
5-hydroxyisourate, which is known to be cytotoxic [35].
Most animals use urate oxidase coupled with 5-hydroxyi-
sourate hydrolase [36, 37] to degrade urate to allantoin.
Urate oxidase produces 5-hydroxyisourate without releas-
ing reactive intermediates while 5-hydroxyisourate hydro-
lase prevents accumulation of this toxic metabolite [35].
Both these enzymes are absent in humans. Thus oxidation
of urate in humans is potentially dangerous because no
enzymes are present to negate the harmful effects of its
oxidation products. Consequently MPO-dependent oxi-
dation of urate may contribute to the sequelae of inflam-
matory diseases, particularly gout.
From our results it is apparent that allopurinol has con-
trasting effects on oxidative stress depending on the oxy-
purinol concentration. Low concentrations of oxypurinol
lowered allantoin. This effect was lost with increasing
plasma concentrations of oxypurinol, to the point where
it increased formation of allantoin. At low concentrations,
oxypurinol should act by decreasing inflammation through
its urate-lowering action. However, high concentrations of
oxypurinol could promote oxidation of urate via two path-
ways (see Fig. 5). First, allopurinol is chiefly metabolized to
oxypurinol by aldehyde oxidase and in the process pro-
duces superoxide and H2O2 [17, 38, 39]. These oxidants
may evade endogenous scavengers and contribute to oxi-
dation of urate by spawning several reactive oxidants.
Secondly, our data show that oxypurinol is a good sub-
strate for the redox intermediates of MPO and gives rise to
a radical that is capable of oxidizing urate. Consequently,
when oxypurinol is metabolized by MPO, related peroxid-
ases or one-electron oxidants, urate will be oxidized and
there will be an increase in the production of allantoin.
Increased MPO and allantoin in patients with acute gout
point to a potential mechanism for the increase in CVD
observed in patients with gout and asymptomatic hyper-
uricaemia [40]. MPO is an emerging player in the promo-
tion and progression of CVD [41, 42]. Once released from
neutrophils, it sticks to the vascular endothelium, where it
generates HOCl that damages endothelial cells. It also
oxidizes low-density lipoprotein (LDL) to a form readily
taken up by macrophages, as well as impairing the re-
verse cholesterol transport function of high-density lipo-
protein (HDL) by selectively nitrating and chlorinating
tyrosine residues [43]. In addition to these oxidative reac-
tions, MPO also scavenges nitric oxide by producing free
radicals, including the urate radical [7, 44]. Depleting nitric
oxide, a potent vasodilator, may lead to hypertension and
endothelial cell dysfunction [44]. Enhanced oxidation of
urate in patients with gout will also result in formation of
cytotoxic urate hydroperoxide and 5-hydroxyisourate [7].
These reactions of MPO-derived oxidants and metabol-
ites of urate link MPO and urate to CVD. In support of this
proposal, MPO is also elevated in RA [45] and promotes
increased oxidation of HDL, especially in those patients
FIG. 5 Oxidative metabolism of urate
Urate is produced by xanthine oxidoreductase (XOR) from
xanthine and in the presence of oxygen can form hydro-
gen peroxide (H2O2) and superoxide (O2
) [16].
Myeloperoxidase (MPO) uses H2O2 to oxidize urate to the
urate radical and to produce hypochlorous acid (HOCl)
from chloride [7, 8]. Urate is also susceptible to one-
electron oxidation by reactive oxygen species (ROS). The
urate radical reacts rapidly with superoxide to form urate
hydroperoxide or is converted to 5-hydroxyisourate.
These electrophilic products can either react or decay to
allantoin. Aldehyde oxidase (AO) oxidizes allopurinol to
oxypurinol, which inactivates xanthine oxidoreductase.
Oxypurinol is oxidized to a radical that promotes the oxi-
dation of urate. Arrows with dashed lines indicate path-
ways with multiple stages between reactants and
products. Urate is toxic because it can crystalize and
activate the NACHT, LRR and PYD domains-containing
protein 3 (NALP3) inflammasome or is oxidized to the re-
active species shown in italics. Allantoin is a stable bio-
marker of oxidative stress.
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with CVD [45]. Further long-term clinical studies are
required to determine the association between MPO and
CVD in patients with gout.
Successful long-term management of gout requires a
sustained reduction of plasma urate to <360mM and po-
tentially <300mM if tophi are present. Achieving this target
is associated with improved clinical outcomes [4648]. It
is plausible that achieving the target will also have a bene-
ficial effect on cardiovascular outcomes in patients with
gout by lowering inflammation and associated oxidative
stress. However, the target concentration of urate is more
likely to be obtained with a plasma oxypurinol concentra-
tion between 100 and 150mM [21]. These concentrations
of oxypurinol tilt the antioxidant/oxidant balance to a pro-
oxidant position by increasing the production of reactive
oxygen species, as observed by the elevation in plasma
allantoin. Whether this effect is clinically relevant will
require long-term clinical trials to ascertain, but it raises
the issue of how long patients need to maintain the target
plasma urate concentration once attacks of gout and
tophi have abated. A two-phase approach to treatment
has been suggested whereby the lower urate target
must be achieved in the first phase but once attacks of
gout and tophi have resolved a higher target may be ac-
ceptable [49]. This may have benefits if lower doses of
allopurinol, and hence lower plasma oxypurinol concen-
trations, could be used in the second phase to minimize
oxidative stress.
In conclusion, we have found that elevated MPO and
urate oxidation are associated with gout. In future work
valuable mechanistic insights into the link between hyper-
uricaemia and inflammatory diseases may become appar-
ent when probing the involvement of MPO-dependent
oxidative stress, especially that related to oxidation pro-
ducts of urate.
Rheumatology key messages
. Circulating MPO is elevated during acute gout.
. High urate in gout is associated with increased
oxidative stress.
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